2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
20
Recruiting
9
Unknown
3
Terminated
2
Not yet recruiting
2
Enrolling by invitation
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Thromboprophylaxis
1
Pulmonary Embolism
1
Neoplasms
1
Interventions
Cisplatin
122
Carboplatin
121
Drug Therapy
118
Bevacizumab
105
Capecitabine
99
Oxaliplatin
97
Radiotherapy
95
Paclitaxel
88
Gemcitabine
88
tislelizumab
87
Cyclophosphamide
86
Specimen Handling
80
pembrolizumab
76
toripalimab
67
Magnetic Resonance Spectroscopy
65
Fluorouracil
62
sintilimab
59
Injections
57
Surgical Procedures, Operative
56
Docetaxel
54
anlotinib
51
130-nm albumin-bound paclitaxel
48
Immune Checkpoint Inhibitors
47
fludarabine
46
Standard of Care
45
Pemetrexed
43
Blood Specimen Collection
43
Biopsy
43
venetoclax
41
lenvatinib
41
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Not yet recruiting
×
apixaban
×
Clear all
NCT07493304
2026-03-25
ROXI-CAT-II
Regeneron Pharmaceuticals
Phase 3
Not yet recruiting
1,600 enrolled
NCT07160686
2025-09-08
THROMBO-STOP
University of Birmingham
Phase 3
Not yet recruiting
1,456 enrolled